ANGELICO, MARIO
 Distribuzione geografica
Continente #
NA - Nord America 87.132
EU - Europa 5.109
AS - Asia 2.821
SA - Sud America 33
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 13
OC - Oceania 13
Totale 95.137
Nazione #
US - Stati Uniti d'America 87.104
SG - Singapore 1.258
UA - Ucraina 1.210
CN - Cina 1.069
DE - Germania 976
IE - Irlanda 764
IT - Italia 507
SE - Svezia 454
KR - Corea 334
FI - Finlandia 258
FR - Francia 245
GB - Regno Unito 228
PL - Polonia 177
RU - Federazione Russa 170
JP - Giappone 37
BE - Belgio 35
VN - Vietnam 30
CZ - Repubblica Ceca 24
IN - India 24
CA - Canada 23
BR - Brasile 19
NL - Olanda 15
RO - Romania 14
HK - Hong Kong 13
AU - Australia 12
CL - Cile 10
EU - Europa 10
PK - Pakistan 10
CH - Svizzera 8
IL - Israele 7
A2 - ???statistics.table.value.countryCode.A2??? 6
EG - Egitto 6
IR - Iran 6
KG - Kirghizistan 6
TR - Turchia 6
ET - Etiopia 5
ES - Italia 4
TM - Turkmenistan 4
TW - Taiwan 4
DM - Dominica 3
GR - Grecia 3
EC - Ecuador 2
HU - Ungheria 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NO - Norvegia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
DK - Danimarca 1
EE - Estonia 1
ID - Indonesia 1
IQ - Iraq 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
MX - Messico 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
TH - Thailandia 1
VA - Santa Sede (Città del Vaticano) 1
Totale 95.137
Città #
Woodbridge 27.064
Wilmington 23.543
Houston 21.597
Fairfield 2.718
Ann Arbor 1.968
Jacksonville 1.127
Ashburn 1.123
Seattle 1.104
Chandler 1.082
Singapore 1.080
Cambridge 912
Dublin 745
Medford 575
Dearborn 515
Beijing 414
Santa Clara 287
Lawrence 267
Rome 219
New York 203
Zhengzhou 202
Mülheim 190
Kraków 174
Hangzhou 136
San Diego 135
Menlo Park 121
Milan 77
Moscow 77
Palo Alto 54
University Park 52
Shanghai 48
Mountain View 46
Hefei 42
Falls Church 40
Norwalk 40
Redwood City 38
Boardman 36
San Mateo 36
Brussels 34
Nanjing 32
Verona 32
Detroit 30
San Francisco 28
London 27
Guangzhou 25
Kunming 23
Indiana 20
Seoul 20
Helsinki 18
Hanoi 17
Jinan 16
Los Angeles 15
Nanchang 15
Saint Petersburg 15
Phoenix 14
São Paulo 14
Olomouc 13
Creede 12
Munich 12
Iasi 11
Toronto 11
Auburn Hills 9
Colorado Springs 9
Dong Ket 9
Seongnam 9
Brno 8
Chengdu 8
Frankfurt am Main 8
Fuzhou 8
Hebei 8
Hong Kong 8
Nuremberg 8
Redmond 8
Shenyang 7
Changsha 6
Groningen 6
Wuhan 6
Ypsilanti 6
Chiswick 5
Hounslow 5
Lahore 5
Mcallen 5
New Bedfont 5
Yellow Springs 5
Bologna 4
Canberra 4
Engelhard 4
Florence 4
Fremont 4
Irvine 4
Kilburn 4
La Veta 4
San Jose 4
Shaoxing 4
Simi Valley 4
Storm Lake 4
Taipei 4
Washington 4
Baotou 3
Bari 3
Bengaluru 3
Totale 88.767
Nome #
Crusted scabies in a liver transplant patient mimicking rupioid psoriasis 1.354
Boceprevir for untreated chronic HCV genotype 1 infection. 543
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 510
Transport, utilization and biliary secretion of lysophosphatidylcholine in the rat liver 478
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 452
Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C 450
Operational tolerance in clinical liver transplantation: emerging developments. 444
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 444
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 443
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 443
Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease 440
Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans 438
Primary yolk sac tumor of the liver: incidental finding in a patient transplanted for hepatocellular carcinoma 438
Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization 437
Glycogen storage disease type Ia and VI associated with hepatocellular carcinoma: Two case reports 436
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 433
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 432
Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers 431
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 427
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. 424
Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats 424
Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation. 423
Recurrence of insulin resistant metabolic syndrome following liver transplantation 422
In vivo, high field, 3-Tesla H MR spectroscopic asessment of liver in fibrosis in HCV-correlated chronic liver disease Valutazione in vivo della fibrosi epatica in corso di epatopatia cronica HCV con spettroscopia H-RM 3T 422
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo. 421
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 421
Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. 420
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late 420
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 419
Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders 418
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial 418
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study 418
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 418
Liver elasticity in NASH patients evaluated with real-time elastography (RTE). 417
Interposition of the right colic angle between the liver and thoracic wall: an unusual cause of massive rectal bleeding following percutaneous biopsy in a liver transplant recipient. 414
Leptin attenuates ischemia-reperfusion injury in the rat liver. 413
Quasielastic light scattering evidence for vesicular secretion of biliary lipids 412
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 412
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
N-ethyl-tauroursodeoxycholic acid, a novel deconjugation-resistant bile salt analogue: effects of acute feeding in the rat 410
Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!". 409
High performance liquid chromatographic analysis of molecular species of phosphatidylcholine--development of quantitative assay and its application to human bile 409
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients 409
A randomized controlled trial of amantadine plus interferon-alpha 2a vs. interferon-alpha 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha 2a monotherapy 408
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. 408
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 408
Effect of glucose and/or branched chain amino acid infusion on plasma amino acid imbalance in chronic liver failure 408
Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study 408
Interposition of the right colic angle between the liver and thoracic wall: An unusual cause of massive rectal bleeding following percutaneous biopsy in a liver transplant recipient 407
Hepatitis C reinfection after liver transplantation in relation to virus genotype 407
Portal vein thrombosis after radiofrequency ablation of HCC 407
Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension 404
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha 402
Lamellar bodies coexist with vesicles and micelles in human gallbladder bile. Ursodeoxycholic acid prevents cholesterol crystal nucleation by increasing biliary lamellae 402
Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. 401
596 401
Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: preliminary results 401
Metabolic findings after liver transplantation within a randomised trial with or without steroids 401
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients 401
Assembly of biliary lipids in native hepatic bile after orthotopic liver transplantation: a biochemical and ultra-structural study in humans 400
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 400
Spontaneous resolution of severe acute rejection in liver transplantation. 399
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 399
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis 398
Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins 398
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 397
Extended HBV vaccination in liver transplant recipients for HBV-related cirrhosis: report of two successful cases. 396
Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs 396
Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF) 396
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 396
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 395
The meaning of serum bile acid patterns 394
Sulfated bile acids in serum, bile, and urine of cirrhotic patients before and after portacaval anastomosis 394
Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids 394
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 394
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease 393
Qualitative patterns of biliary bile acids affect cyclosporine intestinal absorption in liver transplant recipients 393
Familial factors determine the development of diabetic nephropathy in patients with IDDM 393
International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and UK 393
Liver transplantation in the presence of portal vein thrombosis: report from a single center. 392
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 392
Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia. 392
Spontaneous resolution of severe acute rejection in liver transplantation 392
Influence of portacaval anastomosis on serum and biliary unsulfated bile acid composition in patients with liver cirrhosis 390
Is donor age a risk factor for poor graft function after orthotopic liver transplantation? 389
The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation 389
Erythrocyte fatty acid composition and gallstone disease: results of an epidemiological survey 389
Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort 389
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 389
Evaluation of B-cell secretion and peripheral insulin resistance during pregnancy and after delivery in gestational diabetes mellitus with obesity 388
Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C 387
Long-acting nitrates in portal hypertension: to be or not to be? 387
Human islet allografts in patients with type 2 diabetes undergoing liver transplantation 386
Epidemiology and outcome of hepatitis C relapse in transplant recipients 386
Liver transplantation for end-stage liver disease related to viral hepatitis 385
Gallstones in cystic fibrosis: a critical reappraisal 385
Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response 384
Activation of the IGF1 system characterizes cholangiocyte survival during progression of primary biliary cirrhosis 383
Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis 383
Nodular transformation of the liver: a reply 383
Totale 42.009
Categoria #
all - tutte 167.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 167.842


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019.250 0 0 0 2.319 2.222 2.631 2.180 2.207 2.258 2.093 1.570 1.770
2020/202114.570 1.702 1.781 1.619 1.884 1.487 1.499 1.846 1.386 316 313 576 161
2021/20222.782 122 280 162 157 65 361 121 113 269 248 109 775
2022/20233.217 377 235 125 347 254 745 273 185 300 28 286 62
2023/2024870 134 21 87 20 92 217 15 22 11 23 7 221
2024/20252.153 187 1.299 623 44 0 0 0 0 0 0 0 0
Totale 95.625